Affimed (NASDAQ:AFMD) Receives $45.00 Consensus Price Target from Analysts

Affimed (NASDAQ:AFMD) has been assigned an average rating of “Buy” from the five ratings firms that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $45.00.

Several brokerages have commented on AFMD. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. HC Wainwright upped their price target on Affimed to $10.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Wells Fargo & Company dropped their price target on Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, April 1st. Finally, StockNews.com began coverage on Affimed in a research note on Tuesday, January 2nd. They set a “sell” rating for the company.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently modified their holdings of AFMD. Advisor Group Holdings Inc. boosted its position in shares of Affimed by 258.3% in the first quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 6,464 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Affimed by 23.9% in the first quarter. JPMorgan Chase & Co. now owns 68,895 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 13,300 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Affimed by 1.9% in the first quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company’s stock worth $1,323,000 after buying an additional 5,513 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Affimed in the first quarter worth about $726,000. Finally, Vanguard Group Inc. boosted its position in shares of Affimed by 0.4% in the first quarter. Vanguard Group Inc. now owns 1,386,701 shares of the biopharmaceutical company’s stock worth $6,060,000 after buying an additional 5,499 shares during the period. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Stock Performance

Shares of NASDAQ:AFMD opened at $5.23 on Thursday. The firm has a market capitalization of $79.65 million, a PE ratio of -0.62 and a beta of 2.05. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.25 and a quick ratio of 3.23. The business has a 50-day moving average of $5.55 and a two-hundred day moving average of $5.00. Affimed has a 12 month low of $2.23 and a 12 month high of $11.10.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.